Literature DB >> 12626459

Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease.

Pong Kian Chua1, Marian E Melish, Qigui Yu, Richard Yanagihara, Kara S Yamamoto, Vivek R Nerurkar.   

Abstract

Kawasaki disease (KD) is an acute, self-limiting, multisystem vasculitis of unknown etiology affecting infants and young children. Unless treated promptly with high-dose intravenous gamma globulin and aspirin, patients frequently develop coronary aneurysms. Previously, matrix metalloproteinase 9 (MMP-9), which is secreted complexed to tissue inhibitor of metalloproteinase 1 (TIMP-1), has been implicated in abdominal aortic aneurysm formation. Since the clinical and pathological features of KD include inflammation and weakening of blood vessels, we analyzed acute- and convalescent-phase paired plasma or serum samples from 31 KD patients, 7 patients who did not completely meet the criteria for KD, and 26 non-KD controls (9 febrile and 17 afebrile patients) for pro-MMP-9 (92 kDa) enzyme activity by gelatin zymography and for active MMP-9 (83 kDa), pro-MMP-9, and TIMP-1 protein levels by enzyme-linked immunosorbent assay. Statistical analysis was performed by using Student t tests, linear regression, and the Wilcoxon rank-sum test. Markedly elevated pro-MMP-9 enzymatic activity, pro-MMP-9 protein levels, and TIMP-1 protein levels were found during the acute phase of illness in patients with clinically established KD and in patients who were suspected of having KD but did not meet all of the criteria. There was no significant difference in active MMP-9 levels. Furthermore, pro-MMP-9 and TIMP-1 protein levels were significantly elevated among KD patients, compared to those of febrile and afebrile non-KD controls. The significantly elevated pro-MMP-9 enzyme and protein levels during the acute phase of KD may reflect vascular remodeling or an inflammatory response to a microbial agent, suggesting a pathophysiological role for MMP-9 in coronary aneurysm formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12626459      PMCID: PMC150536          DOI: 10.1128/cdli.10.2.308-314.2003

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  42 in total

1.  Is there an association between Kawasaki disease and Chlamydia pneumoniae?

Authors:  S Strigl; A Kutlin; P M Roblin; S Shulman; M R Hammerschlag
Journal:  J Infect Dis       Date:  2000-06-05       Impact factor: 5.226

2.  Lack of association between Kawasaki syndrome and infection with parvovirus B19, human herpesvirus 8, TT virus, GB virus C/hepatitis G virus or Chlamydia pneumoniae.

Authors:  P K Chua; V R Nerurkar; Q Yu; C L Woodward; M E Melish; R Yanagihara
Journal:  Pediatr Infect Dis J       Date:  2000-05       Impact factor: 2.129

3.  Failure to demonstrate Chlamydia pneumoniae in cardiovascular tissue from children with Kawasaki disease.

Authors:  M R Hammerschlag; J Boman; A H Rowley
Journal:  Pediatr Infect Dis J       Date:  2001-01       Impact factor: 2.129

4.  Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease.

Authors:  D M Hovsepian; S J Ziporin; M K Sakurai; J K Lee; J A Curci; R W Thompson
Journal:  J Vasc Interv Radiol       Date:  2000 Nov-Dec       Impact factor: 3.464

5.  Lack of association between Kawasaki syndrome and Chlamydia pneumoniae infection: an investigation of a Kawasaki syndrome cluster in San Diego County.

Authors:  S J Schrag; R E Besser; C Olson; J C Burns; P M Arguin; F Gimenez-Sanchez; V A Stevens; J M Pruckler; B S Fields; E D Belay; M Ginsberg; S F Dowell
Journal:  Pediatr Infect Dis J       Date:  2000-01       Impact factor: 2.129

6.  Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms.

Authors:  S Yoon; G Tromp; S Vongpunsawad; A Ronkainen; T Juvonen; H Kuivaniemi
Journal:  Biochem Biophys Res Commun       Date:  1999-11-19       Impact factor: 3.575

7.  Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease.

Authors:  S Takeshita; T Tokutomi; H Kawase; K Nakatani; H Tsujimoto; Y Kawamura; I Sekine
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

8.  IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease.

Authors:  A H Rowley; S T Shulman; C A Mask; L S Finn; M Terai; S C Baker; C A Galliani; K Takahashi; S Naoe; M B Kalelkar; S E Crawford
Journal:  J Infect Dis       Date:  2000-09-08       Impact factor: 5.226

9.  Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease.

Authors:  H Senzaki; S Masutani; J Kobayashi; T Kobayashi; H Nakano; H Nagasaka; N Sasaki; H Asano; S Kyo; Y Yokote
Journal:  Circulation       Date:  2001-08-21       Impact factor: 29.690

10.  Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms.

Authors:  W D McMillan; W H Pearce
Journal:  J Vasc Surg       Date:  1999-01       Impact factor: 4.268

View more
  15 in total

1.  Study design and rationale to assess Doxycycline Efficacy in preventing coronary Artery Lesions in children with Kawasaki disease (DEAL trial) - A phase II clinical trial.

Authors:  Andras Bratincsak; Blair N Limm-Chan; Vivek R Nerurkar; Lauren L Ching; Venu D Reddy; Eunjung Lim; Ralph V Shohet; Marian E Melish
Journal:  Contemp Clin Trials       Date:  2017-12-05       Impact factor: 2.226

2.  IL-1 Signaling Is Critically Required in Stromal Cells in Kawasaki Disease Vasculitis Mouse Model: Role of Both IL-1α and IL-1β.

Authors:  Youngho Lee; Daiko Wakita; Jargalsaikhan Dagvadorj; Kenichi Shimada; Shuang Chen; Ganghua Huang; Thomas J A Lehman; Michael C Fishbein; Hal M Hoffman; Timothy R Crother; Moshe Arditi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-10-29       Impact factor: 8.311

3.  Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.

Authors:  Adriana H Tremoulet; Sonia Jain; Pei-Ni Jone; Brookie M Best; Elizabeth H Duxbury; Alessandra Franco; Beth Printz; Samuel R Dominguez; Heather Heizer; Marsha S Anderson; Mary P Glodé; Feng He; Robert L Padilla; Chisato Shimizu; Emelia Bainto; Joan Pancheri; Harvey J Cohen; John C Whitin; Jane C Burns
Journal:  J Pediatr       Date:  2019-09-24       Impact factor: 4.406

Review 4.  Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.

Authors:  Jane C Burns; Isabelle Koné-Paut; Taco Kuijpers; Chisato Shimizu; Adriana Tremoulet; Moshe Arditi
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

Review 5.  The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases.

Authors:  H Senzaki
Journal:  Arch Dis Child       Date:  2006-10       Impact factor: 3.791

6.  Association of the matrix metalloproteinase-3 (-439C/G) promoter polymorphism with Kawasaki disease in Korean children.

Authors:  Young Mi Hong; Hyun-Seung Jin; In Sook Park; Soo-Jong Hong
Journal:  Heart Vessels       Date:  2008-09-20       Impact factor: 2.037

7.  Promoter polymorphism (rs3755724, -55C/T) of tissue inhibitor of metalloproteinase 4 (TIMP4) as a risk factor for Kawasaki disease with coronary artery lesions in a Korean population.

Authors:  Ju Yeon Ban; Kyung Leem Yoon; Su Kang Kim; Sungwook Kang; Joo-Ho Chung
Journal:  Pediatr Cardiol       Date:  2008-12-02       Impact factor: 1.655

8.  Reversal of West Nile virus-induced blood-brain barrier disruption and tight junction proteins degradation by matrix metalloproteinases inhibitor.

Authors:  Saguna Verma; Mukesh Kumar; Ulziijargal Gurjav; Stephanie Lum; Vivek R Nerurkar
Journal:  Virology       Date:  2009-11-18       Impact factor: 3.616

Review 9.  Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature.

Authors:  A K Chow; J Cena; R Schulz
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

10.  The influence of hemodynamic forces on biomarkers in the walls of elastase-induced aneurysms in rabbits.

Authors:  Ramanathan Kadirvel; Yong-Hong Ding; Daying Dai; Hasballah Zakaria; Anne M Robertson; Mark A Danielson; Debra A Lewis; Harry J Cloft; David F Kallmes
Journal:  Neuroradiology       Date:  2007-09-20       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.